{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:58:29Z","timestamp":1790971109628,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HGSRC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Advanced osteosarcomas (OSs) and Ewing sarcomas (ESs) tend to have poor prognosis with limited therapeutic options beyond first-line therapy. Aberrant angiogenesis and MET signaling play an important role in preclinical models. The anti-angiogenic drug cabozantinib was tested in a phase 2 trial of advanced OS and ES and was associated with clinical benefits. We retrospectively analyzed the off-label use of cabozantinib in adult patients with advanced OS and ES\/primitive neuroectodermal tumors (PNETs) in three centers of the Hellenic Group of Sarcoma and Rare Cancers (HGSRC). Between April 2019 and January 2022, 16 patients started taking 60 mg of cabozantinib for advanced bone sarcoma or PNET. Median age at cabozantinib initiation was 31 years (17\u201383). All patients had received peri-operative chemotherapy for primary sarcoma and between 0 and 4 lines of treatment (median; 2.5) for advanced disease. The most common adverse effects included fatigue, anorexia, hypertransaminasemia, weight loss, and diarrhea. One toxic death was noted (cerebral hemorrhage). Dose reduction to 40 mg was required in 31.3% of the patients. No objective response was noted, and 9\/16 patients exhibited stable disease outcomes. Progression-free survival varied from 1 to 8 (median; 5) months. Our study demonstrates that cabozantinib has antitumor activity in this population. In the real-life setting, we observed similar adverse events as in the CABONE study and in other neoplasms.<\/jats:p>","DOI":"10.3390\/jcm12031119","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T01:36:59Z","timestamp":1675215419000},"page":"1119","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers"],"prefix":"10.3390","volume":"12","author":[{"given":"Stefania","family":"Kokkali","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece"},{"name":"Medical Oncology Unit, Department of Internal Medicine, Hippocratio General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Kyriazoglou","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpida","family":"Mangou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8871-3264","authenticated-orcid":false,"given":"Panagiota","family":"Economopoulou","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Panousieris","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Psyrri","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Ardavanis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Saint-Savvas Anticancer Hospital, 11522 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0580-5663","authenticated-orcid":false,"given":"Nikolaos","family":"Vassos","sequence":"additional","affiliation":[{"name":"Medical Faculty Mannheim, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Boukovinas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Bioclinic Hospital, 54622 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2022, September 13). Bone Cancer (Sarcoma of Bone)\u2014Statistics. Available online: https:\/\/www.cancer.net\/cancer-types\/bone-cancer-sarcoma-bone\/statistics."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(97)02307-6","article-title":"Randomised Trial of Two Regimens of Chemotherapy in Operable Osteosarcoma: A Study of the European Osteosarcoma Intergroup","volume":"350","author":"Souhami","year":"1997","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2002.20.2.426","article-title":"Phase II\/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial","volume":"20","author":"Goorin","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/1096-911X(20001101)35:5<468::AID-MPO5>3.0.CO;2-P","article-title":"Pilot Study of Topotecan and High-Dose Cyclophosphamide for Resistant Pediatric Solid Tumors","volume":"35","author":"Kushner","year":"2000","journal-title":"Med. Pediatr. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/cncr.23586","article-title":"Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults with Refractory Bone Sarcoma","volume":"113","author":"Navid","year":"2008","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1200\/JCO.2011.41.5703","article-title":"Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report from the Children\u2019s Oncology Group","volume":"30","author":"Womer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"11500","DOI":"10.1200\/JCO.2020.38.15_suppl.11500","article-title":"Comparison of Two Chemotherapy Regimens in Ewing Sarcoma (ES): Overall and Subgroup Results of the Euro Ewing 2012 Randomized Trial (EE2012)","volume":"38","author":"Brennan","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pbc.20719","article-title":"Topotecan and Cyclophosphamide in Patients with Refractory or Relapsed Ewing Tumors","volume":"47","author":"Hunold","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and Temozolomide for Ewing Sarcoma: The Memorial Sloan-Kettering Experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/0008-5472.CAN-05-4422","article-title":"MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas","volume":"66","author":"Avnet","year":"2006","journal-title":"Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ijc.28047","article-title":"Expression and Clinical Relevance of MET and ALK in Ewing Sarcomas","volume":"133","author":"Fleuren","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1002\/cncr.26116","article-title":"Genetic Amplification of the Vascular Endothelial Growth Factor (VEGF) Pathway Genes, Including VEGFA, in Human Osteosarcoma","volume":"117","author":"Yang","year":"2011","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cncr.24844","article-title":"Angiogenesis and Vascular Targeting in Ewing Sarcoma: A Review of Preclinical and Clinical Data","volume":"116","author":"DuBois","year":"2010","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100250","DOI":"10.1016\/j.esmoop.2021.100250","article-title":"Phase I\/II Study of Single-Agent Lenvatinib in Children and Adolescents with Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma (ITCC-050)\u2606","volume":"6","author":"Gaspar","year":"2021","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1200\/JCO.18.02374","article-title":"Randomized Double-Blind Phase II Study of Regorafenib in Patients with Metastatic Osteosarcoma","volume":"37","author":"Davis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and Safety of Regorafenib in Adult Patients with Metastatic Osteosarcoma: A Non-Comparative, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A Phase II Trial of Sorafenib in Relapsed and Unresectable High-Grade Osteosarcoma after Failure of Standard Multimodal Therapy: An Italian Sarcoma Group Study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(19)30825-3","article-title":"Cabozantinib in Patients with Advanced Ewing Sarcoma or Osteosarcoma (CABONE): A Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Italiano","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA2","article-title":"Phase III Assessment of Topotecan and Cyclophosphamide and High-Dose Ifosfamide in REECur: An International Randomized Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma (RR-ES)","volume":"40","author":"McCabe","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e11734","DOI":"10.1097\/MD.0000000000011734","article-title":"Efficacy and Safety of Apatinib in Advance Osteosarcoma with Pulmonary Metastases: A Single-Center Observational Study","volume":"97","author":"Zheng","year":"2018","journal-title":"Medicine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"811687","DOI":"10.3389\/fonc.2022.811687","article-title":"Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial","volume":"12","author":"Tang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Palmerini, E., Jones, R.L., Marchesi, E., Paioli, A., Cesari, M., Longhi, A., Meazza, C., Coccoli, L., Fagioli, F., and Asaftei, S. (2016). Gemcitabine and Docetaxel in Relapsed and Unresectable High-Grade Osteosarcoma and Spindle Cell Sarcoma of Bone. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2312-3"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2015.65.5381","article-title":"Outcome of Patients with Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children\u2019s Cancer Group, Pediatric Oncology Group, and Children\u2019s Oncology Group: Learning From the Past to Move Forward","volume":"34","author":"Lagmay","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/pbc.23040","article-title":"Risk of Recurrence and Survival after Relapse in Patients with Ewing Sarcoma","volume":"57","author":"Stahl","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/pbc.25388","article-title":"Post-Relapse Survival in Patients with Ewing Sarcoma","volume":"62","author":"Ferrari","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/S1470-2045(21)00387-9","article-title":"Lenvatinib with Etoposide plus Ifosfamide in Patients with Refractory or Relapsed Osteosarcoma (ITCC-050): A Multicentre, Open-Label, Multicohort, Phase 1\/2 Study","volume":"22","author":"Gaspar","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_29","unstructured":"(2022, August 10). Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_en.pdf."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1119\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:19:54Z","timestamp":1760120394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12031119"],"URL":"https:\/\/doi.org\/10.3390\/jcm12031119","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]}}}